Christopher A Eide Selected Research

Christopher A Eide Research Topics

Disease

28	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2022 - 03/2007
24	Neoplasms (Cancer) 11/2023 - 07/2006
13	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2024 - 07/2006
12	Leukemia 01/2022 - 04/2008
6	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2022 - 07/2010
6	Philadelphia Chromosome 10/2022 - 01/2008
4	Hematologic Neoplasms (Hematological Malignancy) 12/2019 - 01/2016
3	Disease Progression 12/2022 - 01/2011
3	Blast Crisis (Blast Phase) 12/2022 - 04/2017
2	Polycythemia Vera 01/2020 - 01/2018
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 01/2008
2	Lung Neoplasms (Lung Cancer) 01/2016 - 11/2013
2	Adenocarcinoma of Lung 01/2016 - 11/2013
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2015 - 11/2013
1	T-Cell Leukemia (Leukemia, T Cell) 10/2023
1	Splenomegaly 01/2018
1	Juvenile Myelomonocytic Leukemia 01/2018
1	Medulloblastoma 10/2017
1	Chronic Neutrophilic Leukemia 02/2016
1	BCR-ABL Negative Atypical Chronic Myeloid Leukemia (Leukemia, Myeloid, Philadelphia Negative) 02/2016
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2016
1	Renal Cell Carcinoma (Grawitz Tumor) 12/2015
1	Carcinogenesis 11/2014
1	Myeloid Leukemia (Leukemia, Myelocytic) 04/2014
1	Cholangiocarcinoma 11/2013
1	Glioblastoma (Glioblastoma Multiforme) 11/2013
1	Genetic Translocation (Chromosomal Translocation) 01/2008
1	Hodgkin Disease (Hodgkin's Disease) 01/2008

Drug/Important Bio-Agent (IBA)

26	Phosphotransferases (Kinase)IBA 12/2022 - 07/2006
14	Imatinib Mesylate (Gleevec)FDA Link 09/2014 - 03/2007
11	Tyrosine Kinase InhibitorsIBA 01/2021 - 11/2011
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 04/2008
6	ponatinibIBA 10/2019 - 11/2009
6	Dasatinib (BMS 354825)FDA Link 01/2016 - 11/2009
4	venetoclaxIBA 11/2023 - 01/2016
4	Proteins (Proteins, Gene)FDA Link 10/2022 - 11/2013
4	nilotinib FDA Link 12/2011 - 11/2009
3	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 01/2018
3	Oncogene Proteins (Oncogene Protein)IBA 01/2019 - 04/2014
3	DCC-2036IBA 11/2011 - 01/2011
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2024 - 12/2011
2	ibrutinibIBA 01/2020 - 05/2018
2	CrizotinibIBA 01/2016 - 11/2013
2	Anaplastic Lymphoma KinaseIBA 09/2015 - 06/2015
2	Tyrosine (L-Tyrosine)FDA Link 05/2008 - 07/2006
1	Azacitidine (5 Azacytidine)FDA Link 11/2023
1	AntibodiesIBA 10/2023
1	Glycerophospholipids (Phosphoglycerides)IBA 12/2022
1	p38 Mitogen-Activated Protein KinasesIBA 01/2022
1	doramapimodIBA 01/2022
1	Sorafenib (BAY 43-9006)FDA Link 01/2022
1	Mitogen-Activated Protein Kinase 14IBA 01/2022
1	Aurora Kinase AIBA 11/2021
1	NF-kappa B (NF-kB)IBA 01/2021
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2021
1	Adenosine Triphosphatases (ATPase)IBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	Erythropoietin FDA Link 01/2020
1	RNA (Ribonucleic Acid)IBA 12/2019
1	Adenosine Triphosphate (ATP)IBA 01/2019
1	crenolanibIBA 01/2019
1	snake venom protein C activatorIBA 01/2019
1	idelalisibIBA 05/2018
1	BiguanidesIBA 01/2018
1	Metformin (Glucophage)FDA LinkGeneric 01/2018
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018
1	Protein Tyrosine PhosphatasesIBA 01/2018
1	Interleukin-1 (Interleukin 1)IBA 01/2017
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2017
1	Drug CombinationsIBA 01/2017
1	ruxolitinibIBA 02/2016
1	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 02/2016
1	Bcl-2-Like Protein 11IBA 01/2016
1	SolventsIBA 01/2016
1	cabozantinibIBA 01/2016
1	tyrosine receptor (receptor, tyrosine)IBA 12/2015
1	src-Family KinasesIBA 12/2015
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 11/2014
1	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 04/2014
1	Cell-Penetrating PeptidesIBA 04/2014
1	GSK 1363089IBA 11/2013
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 07/2010
1	Amino Acids FDA Link 02/2009
1	Chlorambucil (Leukeran)FDA Link 01/2008
1	bcr-abl Fusion ProteinsIBA 03/2007

Therapy/Procedure

23	Therapeutics 11/2023 - 03/2008
1	Molecular Targeted Therapy 03/2007